Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Gadopentetate dimeglumine
Drug ID BADD_D00991
Description A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see pentetic acid), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706)
Indications and Usage For use with magnetic resonance imaging (MRI) in adults, and pediatric patients (2 years of age and older) to visualize lesions with abnormal vascularity in the brain (intracranial lesions), spine and associated tissues as well as lesions with abnormal vascularity in the head and neck. Also used to facilitate the visualization of lesions with abnormal vascularity in the body (excluding the heart).
Marketing Status Prescription
ATC Code V08CA01
DrugBank ID DB00789
KEGG ID D01707
MeSH ID D019786
PubChem ID 131751658
TTD Drug ID D0RQ2W
NDC Product Code 50419-188
Synonyms Gadolinium DTPA | DTPA, Gadolinium | Gadolinium Diethylenetriaminepenta-acetic Acid | Diethylenetriaminepenta-acetic Acid, Gadolinium | Gadolinium Diethylenetriaminepenta acetic Acid | Gadopentetic Acid | Gd-DTPA | Gd DTPA | Gadolinium DTPA Disodium Salt | Magnograf | Magnograf Enteral | Gadopentetate Dimeglumine | Dimeglumine, Gadopentetate | Gadolinium DTPA Dimeglumine Salt | Gadolinium DTPA Dimeglumine | Dimeglumine, Gadolinium DTPA | Magnevist | Magnevist Enteral
Chemical Information
Molecular Formula C51H82O21
CAS Registry Number 55466-01-8
SMILES CC(=CC1CC(C2C3CCC4C5(CCC(C(C5CCC4(C36CC2(O1)OC6)C)(C)C)OC7C(C(C(CO7)O)OC8C(C(C(C (O8)CO)O)O)OC9C(C(C(CO9)O)O)O)OC1C(C(C(CO1)O)O)O)C)(C)O)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Eye irritation06.04.05.003--Not Available
Eye pain06.08.03.002--
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.003--
Fatigue08.01.01.002--
Feeling cold08.01.09.008--Not Available
Feeling hot08.01.09.009--Not Available
Heart rate decreased13.14.04.001--Not Available
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypotension24.06.03.002--
Injection site reaction12.07.03.015; 08.02.03.014--
Lacrimation increased06.08.02.004--
Laryngeal oedema10.01.05.003; 23.04.01.005; 22.04.02.001--
Laryngospasm22.04.02.002--
Loss of consciousness17.02.04.004--Not Available
Micturition urgency20.02.02.006--
Migraine24.03.05.003; 17.14.02.001--Not Available
Pain08.01.08.004--
Pallor24.03.04.001; 23.03.03.031; 08.01.03.032--Not Available
Paraesthesia17.02.06.005--
Parosmia22.04.03.007; 17.04.04.002--Not Available
Pharyngeal oedema22.04.05.003; 10.01.05.016; 23.04.01.016--Not Available
Phlebitis24.05.03.001; 12.02.01.002--
Pruritus23.03.12.001--
Pulmonary oedema22.01.03.003; 02.05.02.003--
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Rash pustular23.03.10.003; 11.01.12.002--
Respiratory arrest22.02.01.009--Not Available
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages